Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Next Previous
Trial Profile

An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VCTX-211 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 06 May 2025 According to a CRISPR Therapeutics media release, the Company expects to provide an update in 2025.
  • 21 Feb 2023 According to a CRISPR Therapeutics media release, enrollment an dosing is ongoing in this trial.
  • 21 Feb 2023 Status changed from not yet recruiting to recruiting, according to a CRISPR Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top